Skip to content
Clinical Trials – home
Recruiting

Study on Meropenem Dosing for Patients with Serious Infections in Intensive Care

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on treating serious infections that require broad-spectrum antibiotics. The study is examining the use of the antibiotic Meropenem, which is commonly used in hospitals to treat severe infections. The trial aims to find the best way to administer this medication to patients in the intensive care unit (ICU). Specifically, it compares two different dosing schedules: one where Meropenem is given in short infusions six times a day, and another where it is given in longer infusions three times a day.

The purpose of the study is to determine if the shorter, more frequent dosing is as effective as the longer, less frequent dosing. Participants in the study will receive one of these two dosing schedules while they are in the ICU. The study will monitor how well the medication works in maintaining adequate levels in the body, as well as other factors like the length of stay in the ICU and any serious side effects that may occur.

This trial is important for optimizing the treatment of serious infections in critically ill patients. By comparing these two dosing methods, the study hopes to improve the effectiveness of Meropenem and potentially enhance patient outcomes in the ICU setting. The study will run for a period of time, and results will be collected to assess which dosing schedule provides the best results for patients.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant must be at least 18 years old and admitted to the intensive care unit with a confirmed or suspected serious infection.

    The participant or their next of kin must provide informed consent to participate in the study. If the participant is unable to consent due to medical reasons, consent may be obtained from the next of kin.

  2. Step 2

    Treatment initiation

    The treatment involves the administration of meropenem, a broad-spectrum antibiotic, for at least 3 days.

    Participants will receive meropenem either as 1 gram infusions over 15 minutes, six times daily, or as 2 grams infusions over 3 hours, three times daily.

  3. Step 3

    Monitoring and assessment

    The primary goal is to ensure that the concentration of meropenem in the blood remains above 2 mg/l for more than 50% of the time each day.

    Participants will be monitored to assess the effectiveness of the dosing regimen over the course of 1, 2, and 3 days.

  4. Step 4

    Evaluation of outcomes

    Secondary outcomes include the length of stay in the intensive care unit, mortality 30 days after admission, and any serious adverse events.

    The study aims to determine if the more frequent, shorter infusions are as effective as the standard dosing regimen.

Who can join the trial?

7 criteria

  • Participants must be at least 18 years old to give their agreement to join the study.
  • The participant must be staying in the Intensive Care Unit at Oslo University Hospital, Rikshospitalet.
  • The participant must have a confirmed or suspected **serious infection**. This means an infection that is severe and requires strong antibiotics.
  • There must be a need for treatment with **meropenem** for at least 3 days. Meropenem is a type of strong antibiotic used to treat serious infections.
  • The patient or their family member must agree to participate in the study.
  • Both men and women can join the study. Women who can have children must use birth control or take a pregnancy test.
  • If the patient is awake and aware, they will be asked to agree to join the study. If the patient cannot agree because they are sedated or on a breathing machine, a family member will be asked for agreement, which can be delayed until the next day.

Who cannot join the trial?

1 criterion

  • Having a serious infection that requires treatment with a broad-spectrum antibiotic. This means an infection that is severe and needs strong antibiotics that can fight a wide range of bacteria.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Meropenem is an antibiotic used to treat serious infections caused by bacteria. In this study, it is being tested to see if giving it in shorter, more frequent doses is as effective as the standard method of giving it in longer, less frequent doses. The goal is to find the best way to administer this medication to patients in the intensive care unit.

What is already known about the treatment

Meropenem – This medication is administered intravenously, typically in a hospital setting, and is used to treat serious infections that require broad-spectrum antibiotics. It is currently well-established in medical practice and literature as an effective treatment for severe bacterial infections, especially in intensive care units. The main therapeutic indication for meropenem is to combat serious infections caused by bacteria that are resistant to other antibiotics. At the molecular level, meropenem works by inhibiting bacterial cell wall synthesis, leading to the death of the bacteria. It belongs to the pharmacological class of carbapenem antibiotics, which are known for their broad-spectrum activity against various bacteria.

Investigated diseases

Serious Infection Requiring Broad-Spectrum Antibiotic – This condition involves a severe infection that necessitates the use of broad-spectrum antibiotics to combat a wide range of bacteria. Such infections can occur in various parts of the body and may lead to significant health issues if not addressed promptly. The progression of the disease can vary depending on the type of bacteria involved and the individual's overall health. Symptoms may include fever, chills, fatigue, and localized pain or swelling. The condition often requires hospitalization and close monitoring to ensure effective management.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-520030-30-00Protocol codeMer-6Estimated enrolment50 patientsSponsorOslo University Hospital HF

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).